Prognostic and predictive biomarkers in melanoma

被引：10

作者：

Maher, Nigel G. ^{[1
,2
,3
,4
]}

Vergara, Ismael A. ^{[1
,4
,5
]}

Long, Georgina V. ^{[1
,4
,5
,6
]}

Scolyer, Richard A. ^{[1
,2
,3
,4
,5
,7
]}

机构：

[1] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[2] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Sydney, NSW, Australia

[3] NSW Hlth Pathol, Sydney, NSW, Australia

[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia

[5] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia

[6] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[7] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Bldg 94 via John Hopkins Dr,Missenden Rd, Camperdown, NSW 2050, Australia

来源：

PATHOLOGY | 2024年 / 56卷 / 02期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

Melanoma; biomarkers; AMERICAN JOINT COMMITTEE; NODE-POSITIVE MELANOMA; STAGE IV MELANOMA; NEOADJUVANT IMMUNOTHERAPY; DESMOPLASTIC MELANOMA; PATHOLOGICAL RESPONSE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; POOLED ANALYSIS; BRAF MUTATIONS;

D O I：

10.1016/j.pathol.2023.11.004

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Biomarkers help to inform the clinical management of patients with melanoma. For patients with clinically localised primary melanoma, biomarkers can help to predict postsurgical outcome (including via the use of risk prediction tools), better select patients for sentinel lymph node biopsy, and tailor catch-all follow-up protocols to the individual. Systemic drug treatments, including immune checkpoint inhibitor (ICI) therapies and BRAF-targeted therapies, have radically improved the prognosis of metastatic (stage III and IV) cutaneous melanoma patients, and also shown benefit in the earlier setting of stage IIB/C primary melanoma. Unfortunately, a response is far from lished, and emerging, prognostic, and predictive pathological biomarkers that refine clinical decision-making in expression profile assays and nomograms are emerging astatic cutaneous melanoma, and the HLA-A*02:01 allele for the use of a bispecific fusion protein in metastatic uveal Australian clinical practice guidelines. Further research, validation, and assessment of clinical utility is required idly integrated into routine care.

引用

页码：259 / 273

页数：15

共 179 条

[81] Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome [J].

Jonsson, Goran ;

Busch, Christian ;

Knappskog, Stian ;

Geisler, Jurgen ;

Miletic, Hrvoje ;

Ringner, Markus ;

Lillehaug, Johan R. ;

Borg, Ake ;

Lonning, Per Eystein .

CLINICAL CANCER RESEARCH, 2010, 16 (13) :3356-3367

[82] Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab [J].

Joseph, Richard W. ;

Elassaiss-Schaap, Jeroen ;

Kefford, Richard ;

Hwu, Wen-Jen ;

Wolchok, Jedd D. ;

Joshua, Anthony M. ;

Ribas, Antoni ;

Hodi, F. Stephen ;

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Dronca, Roxana ;

Hersey, Peter ;

Weber, Jeffrey S. ;

Patnaik, Amita ;

de Alwis, Dinesh P. ;

Perrone, Andrea ;

Zhang, Jin ;

Kang, S. Peter ;

Ebbinghaus, Scot ;

Anderson, Keaven M. ;

Gangadhar, Tara C. .

CLINICAL CANCER RESEARCH, 2018, 24 (20) :4960-4967

[83] Uveal melanoma: Estimating prognosis [J].

Kaliki, Swathi ;

Shields, Carol L. ;

Shields, Jerry A. .

INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (02) :93-102

[84] Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma [J].

Kangas-Dick, Aaron W. ;

Greenbaum, Alissa ;

Gall, Victor ;

Groisberg, Roman ;

Mehnert, Janice ;

Chen, Chunxia ;

Moore, Dirk F. ;

Berger, Adam C. ;

Koshenkov, Vadim .

ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) :4582-4589

[85] Early Detection and Prognostic Assessment of Cutaneous Melanoma Consensus on Optimal Practice and the Role of Gene Expression Profile Testing [J].

Kashani-Sabet, Mohammed ;

Leachman, Sancy A. ;

Stein, Jennifer A. ;

Arbiser, Jack L. ;

Berry, Elizabeth G. ;

Celebi, Julide T. ;

Curiel-Lewandrowski, Clara ;

Ferris, Laura K. ;

Grant-Kels, Jane M. ;

Grossman, Douglas ;

Kulkarni, Rajan P. ;

Marchetti, Michael A. ;

Nelson, Kelly C. ;

Polsky, David ;

Seiverling, Elizabeth V. ;

Swetter, Susan M. ;

Tsao, Hensin ;

Verdieck-Devlaeminck, Alexandra ;

Wei, Maria L. ;

Bar, Anna ;

Bartlett, Edmund K. ;

Bolognia, Jean L. ;

Bowles, Tawnya L. ;

Cha, Kelly B. ;

Chu, Emily Y. ;

Hartman, Rebecca I. ;

Hawryluk, Elena B. ;

Jampel, Risa M. ;

Karapetyan, Lilit ;

Kheterpal, Meenal ;

Lawson, David H. ;

Leming, Philip D. ;

Liebman, Tracey N. ;

Ming, Michael E. ;

Sahni, Debjani ;

Savory, Stephanie A. ;

Shaikh, Saba S. ;

Sober, Arthur J. ;

Sondak, Vernon K. ;

Spaccarelli, Natalie ;

Usatine, Richard P. ;

Venna, Suraj ;

Kirkwood, John M. .

JAMA DERMATOLOGY, 2023, 159 (05) :545-553

[86] Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis [J].

Kolla, Avani M. ;

Vitiello, Gerardo A. ;

Friedman, Erica B. ;

Sun, James ;

Potdar, Aishwarya ;

Daou, Hala ;

Farrow, Norma E. ;

Farley, Clara R. ;

Vetto, John T. ;

Han, Dale ;

Tariq, Marvi ;

Beasley, Georgia M. ;

Contreras, Carlo M. ;

Lowe, Michael ;

Zager, Jonathan S. ;

Osman, Iman ;

Berman, Russell S. ;

Liebman, Tracey N. ;

Stein, Jennifer A. ;

Lee, Ann Y. .

CANCER CONTROL, 2021, 28

[87] Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis [J].

Kuk, Deborah ;

Shoushtari, Alexander N. ;

Barker, Christopher A. ;

Panageas, Katherine S. ;

Munhoz, Rodrigo R. ;

Momtaz, Parisa ;

Ariyan, Charlotte E. ;

Brady, Mary Sue ;

Coit, Daniel G. ;

Bogatch, Kita ;

Callahan, Margaret K. ;

Wolchok, Jedd D. ;

Carvajal, Richard D. ;

Postow, Michael A. .

ONCOLOGIST, 2016, 21 (07) :848-854

[88] Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma [J].

Ladstein, Rita G. ;

Bachmann, Ingeborg M. ;

Straume, Oddbjorn ;

Akslen, Lars A. .

BMC CANCER, 2010, 10

[89] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J-J ;

Rutkowski, P. ;

Lao, C. D. ;

Cowey, C. L. ;

Schadendorf, D. ;

Wagstaff, J. ;

Dummer, R. ;

Ferrucci, P. F. ;

Smylie, M. ;

Hogg, D. ;

Hill, A. ;

Marquez-Rodas, I. ;

Haanen, J. ;

Guidoboni, M. ;

Maio, M. ;

Schoffski, P. ;

Carlino, M. S. ;

Lebbe, C. ;

McArthur, G. ;

Ascierto, P. A. ;

Daniels, G. A. ;

Long, G. V. ;

Bastholt, L. ;

Rizzo, J. I. ;

Balogh, A. ;

Moshyk, A. ;

Hodi, F. S. ;

Wolchok, J. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546

[90]

Lee JY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-15726-7, 10.1038/s41467-020-16080-4]

← 4 5 6 7 8 9 10 11 12 13 →